CTIS2023-504171-24-00招募中1 期
DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry. - DUPI REDUCE trial
Amsterdam UMC0 个研究点目标入组 216 人开始时间: 2023年3月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •The subject is an adult., The subject has a diagnosis of atopic eczema., The subject receives dupilumab 300 mg every 2 weeks for the treatment of atopic eczema., The subject has controlled disease according to the Treat-to-Target criteria., The subject has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.
排除标准
- •The subject uses or initiates other systemic immunomodulating therapy for atopic eczema or another diagnosis.
研究者
相似试验
招募中
4 期
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic EczemaAtopic Dermatitis EczemaAtopic DermatitisNCT06004986Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)216
已完成
3 期
Evaluation of Dupilumab in Patients With Severe Steroid Dependent AsthmaAsthmaNCT02528214Sanofi210
已完成
2 期
Dupilumab in CRSsNPChronic Rhinosinusitis Without Nasal PolypsChronic SinusitisSinus DisorderRespiratory DisorderSinusitisNCT04678856Sanofi71
已完成
3 期
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)Eosinophilic Esophagitis (EoE)NCT04394351Regeneron Pharmaceuticals102
已完成
3 期
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)Dermatitis, AtopicNCT03345914Regeneron Pharmaceuticals367